ArticleFrontiers in oncology2025
Association of dynamic changes in metabolic syndrome components with clinical outcomes in diffuse large B-cell lymphoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Lipid Metabolism Reprogramming in Diffuse Large B-Cell Lymphoma (DLBCL): Mechanisms and Treatment Strategies.Cancers · 2026Review
- Pretreatment TyG-BMI predicts CD19 CAR-T persistence and prognosis in diffuse large B-cell lymphoma.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma (NHL), with 20-40% of patients experiencing poor outcomes despite advancements in treatment. While Metabolic Syndrome (MetS) has been linked to NHL prognosis, its impact on DLBCL outcomes remains unclear. Methods: This study examined the effects of dynamic changes in MetS components on DLBCL treatment outcomes and prognosis. We retrospectively analyzed 125 newly diagnosed DLBCL patients treated with 6-8 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like regimens, with or without rituximab, from May 2010 to May 2022. Group-based trajectory models were used to identify MetS component trajectories. Multivariate logistic regression and Cox proportional hazards regression were employed to determine factors affecting complete remission (CR), progression-free survival (PFS), and overall survival (OS). Results: The 2-year PFS and OS rates were 70.0% and 82.0%, respectively. High baseline high-density lipoprotein cholesterol (HDL-C) was associated with reduced progression risk (HR = 0.27, 95% CI: 0.10-0.78), while high baseline low-density lipoprotein cholesterol (LDL-C) was linked to decreased CR rate (OR = 0.65, 95% CI: 0.44-0.97) and increased progression risk (HR = 1.78, 95% CI: 1.14-2.79). Additionally, high LDL-C trajectory was associated with reduced CR rates, whereas moderate BMI trajectory was associated with improved CR, PFS, and OS. Discussion: Therefore, controlling LDL-C levels and maintaining a moderate BMI are crucial for improving DLBCL clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.